AusperBio Reports Sustained Functional Cure up to 15 Months Off All HBV Treatment in Treatment-Naïve and NA-Treated Patients with Chronic Hepatitis B

Barchart · 14h ago

Long-term follow-up supports AHB-137 as a potential finite-duration therapy; data featured in two late-breaking oral presentations at AASLD The Liver Meeting® 2026

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.